首页|清肝益脾胶囊对四氯化碳诱导大鼠肝纤维化的保护作用及对肠道菌群的影响

清肝益脾胶囊对四氯化碳诱导大鼠肝纤维化的保护作用及对肠道菌群的影响

扫码查看
目的:研究清肝益脾胶囊(Qinggan Yipi Capsules,简称QgYp)对四氯化碳诱导大鼠肝纤维化(hepatic fibrosis,HF)的保护作用,并初步探讨其通过调节肠道菌群改善HF的机制。方法:36只SD大鼠随机分成正常组、模型组、QgYp低剂量组、QgYp中剂量组、QgYp高剂量组和秋水仙碱组,腹腔注射四氯化碳油溶液构建HF大鼠模型,第4周后给予药物干预直至第8周;采用HE、Masson染色,光镜下观察病理变化;采用全自动生化分析仪检测血清谷草转氨酶(AST)、谷丙转氨酶(ALT)含量;采用ELISA检测血清透明质酸(HA)、层黏连蛋白(LN)、Ⅲ型前胶原(PC Ⅲ)、Ⅳ型胶原(Ⅳ-C)含量。另取24只SD大鼠随机分为正常组、模型组、QgYp中剂量组,同上方法建模与给药,于8周后收集盲肠内容物,采用16S rRNA测序技术检测肠道菌群。结果:与模型组相比,QgYp各组大鼠肝脏系数显著降低(P<0。05),肝组织纤维病变和胶原纤维沉积显著改善(P<0。05);QgYp中剂量组、QgYp高剂量组ALT、AST、HA、PCⅢ、LN、Ⅳ-C含量显著降低(P<0。05),且2组差异无统计学意义(P>0。05)。肠道菌群检测结果显示,QgYp可增加HF大鼠肠道菌群的丰富度和多样性,改变肠道菌群组成(P<0。01),增加有益菌g__norank f__norank o__Clostridia_UCG-014、阿克曼氏菌属的丰度占比,降低有害菌罗姆布茨菌属、经黏液真杆菌和狭义梭菌属1的丰度占比。结论:QgYp可改善四氯化碳诱导的大鼠肝纤维化,其机制与调节肠道菌群多样性和丰度相关。
The protective effect of Qinggan Yipi Capsules on carbon tetrachloride-induced hepatic fibrosis in rats and its impact on gut microbiota
OBJECTIVE To investigate the protective effect of Qinggan Yipi Capsules(QgYp)on carbon tetrachloride-in-duced hepatic fibrosis(HF)in rats and explored the potential mechanism of QgYp in improving HF through regulating intesti-nal microbiota.METHODS A total of 36 Sprague-Dawley rats were randomly divided into the following groups:normal group,model group,low-dose QgYp group,medium-dose QgYp group,high-dose QgYp group,and colchicine group.Hepatic fibro-sis was induced by intraperitoneal injection of carbon tetrachloride oil solution.After 4 weeks,drug intervention was initiated and continued until the 8th week.Pathological changes were observed under a light microscope using HE and Masson staining.The levels of serum aspartate aminotransferase(AST)and alanine aminotransferase(ALT)were determined using an automa-ted biochemical analyzer.The serum levels of hyaluronic acid(HA),laminin(LN),procollagen type Ⅲ(PC Ⅲ),and collagen type Ⅳ(Ⅳ-C)were measured using ELISA.Additionally,another 24 Sprague-Dawley rats were randomly assigned to the nor-mal group,model group,and medium-dose QgYp group.The same methods of modeling and drug administration as mentioned above were used,and after 8 weeks,cecal contents were collected for analysis of gut microbiota using 16S rRNA sequencing technology.RESULTS Compared to the model group,the rats in the various QgYp groups exhibited a significant increase in body weight(P<0.05).Additionally,the liver weight and liver coefficient significantly decreased(P<0.05).The his-topathological examination revealed a significant improvement in liver tissue fibrosis and collagen fiber deposition(P<0.05).In the QgYp moderate-dose group and QgYp high-dose group,the levels of ALT,AST,HA,LN、PC Ⅲ,and Ⅳ-C were sig-nificantly reduced(P<0.05),and there was no significant difference between the two groups.The analysis of gut microbiota demonstrated that QgYp increased the richness and diversity of the gut microbiota in HF rats and altered the composition of the gut microbiota(P<0.01).QgYp supplementation led to an increased abundance of beneficial bacteria,such as g__norank_f__norank_o__Clostridia_UCG-014 and Akkermansia,while decreasing the abundance of harmful bacteria,such as Romboutsia,Blautia,and Clostridium sensu stricto 1.CONCLUSION QgYp exhibits the potential to ameliorate carbon tetrachloride-in-duced hepatic fibrosis in rats,and its mechanism is associated with the modulation of gut microbiota diversity and abundance.

Qinggan Yipi Capsulesrats with hepatic fibrosiscarbon tetrachloridegut microbiota

薛文静、苏子衡、张露蓉、潘韵芝、刘海青、王斯琦、程军平

展开 >

南京中医药大学附属苏州市中医医院中心实验室,江苏苏州 215009

苏州市第五人民医院药学部,江苏苏州 215131

清肝益脾胶囊 肝纤维化大鼠 四氯化碳 肠道菌群

第五批姑苏卫生人才培养项目苏州市科技发展计划(医疗卫生科技创新-医学创新应用研究)指导性项目苏州市"科教兴卫"青年科技项目

GSWS2020094SKYXD2022099KJXW2022048

2023

中国医院药学杂志
中国药学会

中国医院药学杂志

CSTPCD北大核心
影响因子:1.198
ISSN:1001-5213
年,卷(期):2023.43(24)
  • 28